Lotus Tissue Repair Lands $26,000,000 Series A Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=631e92cc-2f10-4659-bf91-4c2bc43bcd75&Preview=1 -
Date
6/30/2011 -
Company Name
Lotus Tissue Repair -
Mailing Address
One Mifflin Place Cambridge, MA 02138 -
Company Description
Lotus Tissue Repair is developing its proprietary recombinant human collagen Type VII (rC7) technology as a treatment for dermatologic conditions in which rC7 may play an important role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions. -
Website
http://www.lotustissuerepair.com -
Transaction Type
Venture Equity -
Transaction Amount
$26,000,000 -
Transaction Round
Series A -
Proceeds Purposes
Proceeds of the financing will be used to advance the company’s proprietary recombinant collagen type VII (rC7) technology as the first and only protein replacement therapy in development for the treatment of dystrophic epidermolysis bullosa (DEB), an orphan disease that causes devastating skin blisters, morbidity and early mortality -
M&A Terms
-
Venture Investor
Third Rock Ventures -
Venture Investor
Third Rock Ventures -
Venture Investor
Undisclosed
